KEYTRUDA (Pembrolizumab)

KEYTRUDA (Pembrolizumab)

Vendor
MERCK
Regular price
$5,499.99 USD
Sale price
$5,499.99 USD
Regular price
Sold out
Unit price
per 
Shipping calculated at checkout.

prescription refrigerated

What is this medication? 

KEYTRUDA (Pembrolizumab)
Antineoplastic Agent, Anti-PD-1 Monoclonal Antibody; Immune Checkpoint Inhibitor

KEYTRUDA (Pembrolizumab) is indicated for the treatment of breast cancer, cervical cancer, cutaneous squamous cell carcinoma, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, hepatocellular carcinoma, Hodgkin lymphoma, melanoma, Merkel cell carcinoma, non-small cell lung cancer, primary mediastinal large B-cell lymphoma, renal cell carcinoma, tumor mutational burden-high cancer, urothelial carcinoma.

How does this medication work? 

Pembrolizumab, is a highly selective anti-PD-1 humanized monoclonal antibody which inhibits programmed cell death-1 (PD-1) activity by binding to the PD-1 receptor on T-cells to block PD-1 ligands (PD-L1 and PD-L2) from binding. Blocking the PD-1 pathway inhibits the negative immune regulation caused by PD-1 receptor signaling. Anti-PD-1 antibodies, such as Pembrolizumab reverse T-cell suppression and induce antitumor responses.

How should I take this medication? 

IV: Inject 200mg intravenously once every 3 weeks or 400mg once every 6 weeks.

How to Take:  Infuse over 30 minutes through a 0.2 to 5 micron sterile, nonpyrogenic, low-protein binding inline or add-on filter. Do not infuse other medications through the same infusion line.  Interrupt or slow the infusion for grade 1 or 2 infusion-related reactions; permanently discontinue for grade 3 or 4 infusion-related reactions.

What should I watch for while using this medication? 

Before using KEYTRUDA (Pembrolizumab), make sure your physician is aware of any allergies or medications you currently take, pre-existing medical conditions and activities you perform. Pembrolizumab can potentially induce immune-mediated adverse reactions during and after treatment.  Immune-mediated rash or dermatitis have occurred with Pembrolizumab. Pembrolizumab has been associated with immune-mediated endocrinopathies such as adrenal insufficiency, diabetes, hypophysitis, and thyroid disorders. Pembrolizumab has also been associated with additional immune-mediated toxicities such as colitis, hepatotoxicity, nephrotoxicity, ocular toxicity, and pulmonary toxicity.  Infusion-related reactions (including severe and life-threatening cases) have also occurred.

What if I miss a dose?

If a planned dose of KEYTRUDA (Pembrolizumab) is missed, it should be administered as soon as possible. The schedule of administration should be adjusted to maintain the prescribed dosing interval.

Call your doctor right away to reschedule your appointment.

How should I store this medication?

The reconstituted and/or diluted product should be used immediately. If not used immediately, reconstituted and diluted solutions of KEYTRUDA (Pembrolizumab) solutions may be stored at room temperature for no more than 6 hours from the time of dilution. Reconstituted and diluted solutions may also be stored refrigerated at 2°C to 8°C. If refrigerated, allow the vials to come to room temperature prior to use.

What are the possible side effects of using this medication?

Peripheral edema, cardiac arrhythmia, pruritus, skin rash, vitiligo, hyperglycemia, hyponatremia, hypoalbuminemia, hypertriglyceridemia, hypophosphatemia, hypocalcemia, hypercalcemia, hyperkalemia, decreased serum bicarbonate, hypomagnesemia, hypercholesterolemia, hypokalemia, hypoglycemia, hypothyroidism, hypomagnesemia, weight loss, diarrhea, decreased appetite, constipation, abdominal pain, nausea, vomiting, hematuria, urinary tract infection, lymphocytopenia, anemia, leukopenia, neutropenia, thrombocytopenia, increased INR, hemorrhage, prolonged partial thromboplastin time, increased serum alkaline phosphatase, increased serum transaminases, increased serum aspartate aminotransferase, increased serum alanine aminotransferase, increased liver enzymes, graft versus host disease, infection, fatigue, pain, headache, musculoskeletal pain, arthralgia, myalgia, back pain, asthenia, increased serum creatinine, upper respiratory tract infection, cough, dyspnea, pneumonia, flu-like symptoms, fever.

Note this is not a complete list of side effects for KEYTRUDA (Pembrolizumab), only common ones.